Causes and Diagnostic Considerations of Elevated Free Kappa Light Chains

Introduction to Elevated Free Kappa Light Chains

Elevated free kappa light chains are most commonly caused by plasma cell disorders, particularly multiple myeloma, but can also occur in other hematologic malignancies, renal impairment, and inflammatory conditions 1, 2

Monoclonal Gammopathy of Undetermined Significance (MGUS) is defined by abnormal free light chain ratio (<0.26 or >1.65) and increased level of the involved light chain 2
Light Chain MGUS is characterized by abnormal FLC ratio, increased involved light chain, no immunoglobulin heavy chain expression on immunofixation, clonal bone marrow plasma cells <10%, and absence of end-organ damage 1

Light Chain Cast Nephropathy occurs when overproduced monoclonal free light chains interact with Tamm-Horsfall protein in the loop of Henle to form casts that obstruct tubules 3, 4
Light Chain Deposition Disease is characterized by nodular sclerosing glomerulopathy due to deposition of monoclonal light chains 5
AL Amyloidosis results from tissue deposition of light chains forming amyloid fibrils 5

Normal kappa:lambda ratio is 0.26-1.65; in severe renal impairment (CKD stage 5), the normal ratio can rise to 0.34-3.10 6
High ratio indicates a kappa clone, while a low ratio indicates a lambda clone 6
Serum free light chain concentration >50 mg/dL is associated with risk of renal impairment, with risk significantly increasing when concentration exceeds 80-200 mg/dL 3, 4

Initial evaluation should include measurement of serum creatinine, electrolytes, and estimate glomerular filtration rate (eGFR) 6
Serum protein electrophoresis (SPEP) and serum immunofixation electrophoresis (SIFE) should be performed 6
Collect 24-hour urine for protein electrophoresis and immunofixation 6
Assess complete blood count for cytopenias 6
If monoclonal protein is detected, consider bone marrow biopsy to assess for plasma cell disorders 6
If renal impairment is present, consider renal biopsy to determine if light chain-related kidney disease is present 5, 6
Imaging studies to evaluate for bone lesions if multiple myeloma is suspected 6

For light chain cast nephropathy, rapid reduction of free light chains is crucial for renal recovery 3, 4
Bortezomib-containing regimens are recommended for patients with light chain-related kidney disease 6
Follow-up of patients with monoclonal gammopathy should be based on risk stratification, with high-risk patients requiring more frequent monitoring 7
Avoid nephrotoxic medications in patients with elevated free light chains to prevent further kidney damage 6